Johnson & Johnson ($JNJ) and Pharmacyclics ($PCYC) nabbed the FDA's new breakthrough designation for their cancer drug ibrutinib, a promising late-stage therapy that will be put in the hands of regulators later this year. Report
| Tuesday, March 17th | 11:30am ET / 8:30am PT | Presented by: Metabolon
Here we describe discovery approaches designed to broadly survey the skin metabolome as well as focused metabolomic assessment of sebum, stratum corneum, skin biopsy, cell culture and reconstructed skin models across a variety of conditions. Further, we share results from recent publications and practical clinical case studies. Register Now!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!